12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Company News  |  Deals

Calistoga, Gilead deal

Gilead plans to acquire cancer and inflammation company Calistoga for $375 million in cash, plus up to $225 million in milestones. Calistoga is developing compounds that target isoforms of ...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >